Sugi Predict

Sugi Predict / Compounds / SCHEMBL692066

SCHEMBL692066

SCHEMBL692066

OCC1CN(Cc2ccccc2)CCN1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 1/20 0.60
▸ SIGMAR1 Q99720 4/20 0.57
▸ ALDH1A1 P00352 3/20 0.49
▸ GBA1 P04062 1/20 0.47
▸ FUCA1 P04066 2/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ CYP2C19 P33261 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ GRIN1 Q05586 1/20 0.44
▸ GRIN2B Q13224 1/20 0.44
▸ BCHE P06276 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ BACE1 P56817 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062715 1.00 LTA4H (0.60) LTA4HSIGMAR1ALDH1A1GBA1FUCA1
SCHEMBL28142979 1.00 LTA4H (0.60) LTA4HSIGMAR1ALDH1A1GBA1FUCA1
Hydrochloric Acid SCHEMBL29701206 0.98 LTA4H (0.59) LTA4HSIGMAR1ALDH1A1GBA1FUCA1
SCHEMBL2016258 0.88 LTA4H (0.57) LTA4HSIGMAR1ALDH1A1GBA1FUCA1
SCHEMBL2016261 0.88 LTA4H (0.57) LTA4HSIGMAR1ALDH1A1GBA1FUCA1
SCHEMBL2019556 0.88 LTA4H (0.57) LTA4HSIGMAR1ALDH1A1GBA1FUCA1
SCHEMBL24350 0.86 LTA4H (0.61) LTA4HSIGMAR1ALDH1A1FUCA1CYP2D6
SCHEMBL18325 0.86 LTA4H (0.61) LTA4HSIGMAR1ALDH1A1FUCA1CYP2D6
SCHEMBL3491795 0.86 LTA4H (0.61) LTA4HSIGMAR1ALDH1A1FUCA1CYP2D6
SCHEMBL14033540 0.85 LTA4H (0.55) LTA4HSIGMAR1ALDH1A1GBA1FUCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106674254-A Quinolone carboxylic acid compounds and intermediates, preparation method and application thereof 广东省中医院 2017-05-17 — — CN claimed
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2026-02-10 — — US disclosed
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-04-03 — — US disclosed
EP-2295438-B2 PROCESS FOR PRODUCING HYDROXYALKYLTRIETHYLENEDIAMINE COMPOUND, AND CATALYST COMPOSITION FOR THE PRODUCTION OF POLYURETHANE RESIN USING THE HYDROXYALKYLTRIETHYLENEDIAMINE COMPOUND TOSOH CORP (JP) 2025-03-26 — — EP disclosed
CN-109251211-B Quinolone carboxylic acid compound and intermediate thereof, preparation method and application 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 2025-03-07 — — CN disclosed
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2025-01-07 — — US disclosed
CN-118978535-A C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors 锐新医药公司 2024-11-19 — — CN disclosed
CN-118894869-A C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors 锐新医药公司 2024-11-05 — — CN disclosed
EP-3788050-B1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2024-08-28 — — EP disclosed
CN-112771054-B C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors 锐新医药公司 2024-08-16 — — CN disclosed
US-5849746-A Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists MERCK SHARP & DOHME LTD. (GB) 1998-12-15 — — US disclosed
EP-0807109-A1 SUBSTITUTED 1,4-PIPERAZINE-HETEROARYL DERIVATIVES AS 5-HT 1D? RECEPTOR AGONISTS MERCK SHARP & DOHME LTD. (GB) 1997-11-19 — — EP disclosed
WO-1996023785-A1 SUBSTITUTED 1,4-PIPERAZINE-HETEROARYL DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS MERCK SHARP & DOHME LIMITED (GB) 1996-08-08 — — WO disclosed
US-5116842-A Analgesics GLAXO GROUP LIMITED (GB) 1992-05-26 — — US disclosed
EP-0398720-A2 Piperazine derivatives GLAXO GROUP LIMITED (GB) 1990-11-22 — — EP disclosed
US-4943578-A ANALGESICS; CEREBRAL ANTIISCHEMIC AGENTS GLAXO GROUP LIMITED (GB) 1990-07-24 — — US disclosed
EP-0343900-A2 Piperazine compounds GLAXO GROUP LIMITED (GB) 1989-11-29 — — EP disclosed
US-4766125-A N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia JANSSEN PHARMACEUTICA N.V. (BE) 1988-08-23 — — US disclosed
EP-0068544-B1 NOVEL N-ARYL-PIPERAZINEALKANAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1987-06-03 — — EP disclosed
EP-0068544-A2 Novel N-aryl-piperazinealkanamides JANSSEN PHARMACEUTICA N.V. (BE) 1983-01-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LTA4H 4132/4885SIGMAR1 4218/4885ALDH1A1 4803/4885
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LTA4H 4199/4885SIGMAR1 3879/4885ALDH1A1 4742/4885
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors RICTOR, MTOR, MLST8 LTA4H 4756/4885SIGMAR1 1645/4885ALDH1A1 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.